Ventyx Biosciences (VTYX) Goldman Sachs 45th Annual Global Healthcare Conference summary

Reflections on drug development journey

• Recent years have seen notable drug successes, including a S1P1 drug with unmatched endoscopic remission and a TYK2 compound that met endpoints but lacked competitive differentiation.

• Focus has shifted to a new portfolio centered on NLRP3 compounds, with promising early proof of mechanism in CAPS patients and upcoming obesity studies.

• The team is described as resilient, experienced, and well-adapted to the ups and downs of biotech innovation.

NLRP3 biology and therapeutic rationale

• NLRP3 is a key inflammasome regulating IL-1 beta and IL-18, implicated in multiple diseases when dysregulated.

• There is a bridge between NLRP3 inhibition and the effects seen with IL-1 biologics in cardiovascular and metabolic diseases.

• NLRP3 inhibitors are positioned as potential oral therapies for neurodegenerative, cardiovascular, and obesity indications.

VTX3232 compound development and preclinical data

• VTX3232 was designed internally as a brain-penetrant NLRP3 inhibitor, with strong IP and commercial rights.

• Human phase I data show full biomarker suppression in CSF at doses starting from 10 mg, with a wide safety margin up to 40 mg.

• Mouse studies demonstrated weight loss as monotherapy and additive effects with semaglutide, though mouse data are not directly predictive for humans.

• Combination therapy with GLP-1s is being explored due to potential orthogonal mechanisms affecting feeding behavior and satiety.